Participated in Oyster Therapeutics' $60M Series A led by 4BIO Capital.
NOV 2026
A pharmaceutical biotechnology company developing next-generation targeted protein degraders for neurodegenerative diseases
A pharmaceutical biotechnology company developing next-generation targeted protein degraders for neurodegenerative diseases. Its lead program is an oral, brain-penetrant degrader designed to selectively remove pathological tau while preserving healthy tau, using its proprietary SELFTAC platform to enable smaller degraders that can reach the central nervous system.